The Long and Winding Road for Breast Cancer Biomarkers to Reach Clinical Utility.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 32859655.
- Also identified by DOI 10.1158/1078-0432.CCR-20-2451 and PMC identifier 8791049.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Tumor data from the ABCSG 5 trial of chemotherapy versus endocrine therapy for premenopausal ER<sup>+</sup> breast cancer supports molecular subtyping by Ki-67 IHC as a prognostic marker. But while this tissue was handled uniformly, Ki-67 testing overall is unstandardized, complicating clinical utility. Increasing potential biomarkers herald more challenges in biomarker validation.<i>See related article by Bago-Horvath et al., p. 5682</i>.
Medical subject headings
- Biomarkers, Tumor
- Breast Neoplasms